DeepSeek's global boom has driven a surge in Hong Kong-listed AI stocks, defying market trends. With the Hang Seng Tech Index soaring, AI stocks like Kingsoft Cloud and 4Paradigm have seen significant gains. Previously, Oracle founder Larry Ellison described the "AI plus mRNA vaccine" scenario, sparking immense imagination about AI's potential in mRNA vaccine development.

Riding the wave of the booming global vaccine market, AIM Vaccines (06660.HK), a private Chinese vaccine company, is rapidly rising as a leader in the industry with its exceptional R&D capabilities, extensive product pipeline, and forward-looking international strategy. For investors seeking to invest in the biopharmaceutical sector, AIM Vaccines may represent the innovative force of China's vaccine industry, harboring significant investment potential and value.

AIM Vaccines/Li Fanda, in collaboration with the National Institute of Viral Disease Control and Prevention, published an evaluation of the protective efficacy and safety of their independently developed mRNA rabies candidate vaccine LVRNA001 across different animal models.

AIM Vaccines/Li Fanda, in collaboration with the National Institute of Viral Disease Control and Prevention, published an evaluation of the protective efficacy and safety of their independently developed mRNA rabies candidate vaccine LVRNA001 across different animal models. Studies have shown that repeated administration of LVRNA001 in crab-eating macaques, dogs, and rats does not cause systemic toxicity. It can effectively induce a strong specific immune response against the rabies virus while maintaining a relatively safe profile, indicating that LVRNA001 is a promising rabies vaccine candidate.

Vaccine leader Amy is in the midst of a year of intensive product declaration, and good news has been spreading one after another. According to the company's announcement on December 19th, its new technology route of suspension cultured MDCK cell influenza vaccine and second-generation high-efficiency adsorption tetanus vaccine have successively obtained the "Drug Clinical Trial Approval Notice" from the National Medical Products Administration. This series of developments not only demonstrates the strong innovation and research capabilities of Emmy vaccines, but also opens up vast opportunities for the company's future performance growth.

On November 25th that AIM Vaccine announced that the company held an Investor Open Day on November 21st. CITIC Securities, Guotai Junan, Shenwan Hongyuan, Huaxin Securities, and 57 other securities firms and institutional investors, as well as some industry experts, visited AIM's modern production base in Ningbo to have discussions and exchanges with the management.